MYC and cancer: By identifying this pathway as a susceptibility of KRASG12Ci-resistant tumors, we recommended combinational strategies that could be exploited in KRASG12C-mutated cancer patients and indicated the probabilities of high abundance of c-Myc or ST8SIA6-AS1 as clinical biomarkers during therapy.